Patents by Inventor Priyanka Apurva MADIA

Priyanka Apurva MADIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding anti-TREM-1 antibodies
    Patent number: 11952420
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 9, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11919954
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: March 5, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220348625
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 3, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
  • Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
    Patent number: 11359000
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mary Struthers, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20220002404
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210403561
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
    Patent number: 10787494
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mary Struthers, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190359672
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: June 7, 2019
    Publication date: November 28, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry Davis, Michael Louis Doyle, Priyanka Apurva Madia
  • INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190300592
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
  • ANTI-TREM-1 ANTIBODIES AND USES THEREOF
    Publication number: 20190300608
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia